Scientific exchange · Dr. Ulrich Hayashi

22 Jun 2026 · Virtual · Dr. Ulrich Hayashi, Christie NHS Foundation Trust · MSL Dr. Anna Becker · Nephrada

ReviewedVeeva CRMENG-0155—

Capture insight from this engagement

Location: Christie NHS Foundation Trust
Therapeutic area: Nephrology
Country: United Kingdom
Stakeholder tier: Tier 2
Strategic objective: Not linked
Initiative: Not linked
MSL: ABDr. Anna BeckerMSL, Nephrology (DACH)
Product: Nephrada (nephradin)

Topics discussed

eGFR slope interpretation
Steroid-sparing strategies
Treatment burden and fatigue

Scientific content used

APRIL-IgAN Phase III topline
Surrogate-endpoint evidence review

Questions raised

How does proteinuria reduction at 9 months translate to eGFR benefit?

Notes

Scientific exchange with renal pathologist at Christie NHS Foundation Trust. Discussed egfr slope interpretation, steroid-sparing strategies, treatment burden and fatigue.

Insights captured (1)

Capture insight

INS-0035Medium
eGFR slope interpretation
eGFR slope interpretation: request for data reported by renal pathologist (GB).
Action in progress

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

No follow-ups recorded.

Quality ratings

1–5, rated at review

Scientific relevance: 2
Strategic relevance: 5
Depth of exchange: 1
Actionability: 2

Data lineage

Source system: Veeva CRM
Sync: Veeva CRM · synced 2026-09-15 08:00 UTC
System of record: Veeva CRM
Record id: ENG-0155

Audit history (0)

All create, update and approval events for this record

No audit events in sample data